Virometix raises USD 15 M

Virometix develops fully synthetic vaccines against infectious diseases and cancer, including the anti-pneumococcal candidate V-212, now in Phase I. The USD 15 million round, provided by existing shareholders, will fund the next stage of clinical development.

Announced on
Round
Undisclosed round
Amount
USD 15 M
Location
Schlieren, canton of Zurich
Sector
Biotech & life sciences

Investors

The investors were not named in the announcement.

Preparing a similar round?

The diagnostic shows you the instruments and investors that fit your stage.

Start the diagnostic